Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial

Background: Alternating administration of docetaxel and gemcitabine might result in improved time-to-treatment failure (TTF) and fewer adverse events compared with single-agent docetaxel as treatment of advanced breast cancer. Patients and methods: Women diagnosed with advanced breast cancer were ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Joensuu, H., Sailas, L., Alanko, T., Sunela, K., Huuhtanen, R., Utriainen, M., Kokko, R., Bono, P., Wigren, T., Pyrhönen, S., Turpeenniemi-Hujanen, T., Asola, R., Leinonen, M., Hahka-Kemppinen, M., Kellokumpu-Lehtinen, P.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860103/
https://www.ncbi.nlm.nih.gov/pubmed/19819914
http://dx.doi.org/10.1093/annonc/mdp397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860103/
https://www.ncbi.nlm.nih.gov/pubmed/19819914
http://dx.doi.org/10.1093/annonc/mdp397

Ejemplares similares